EGFR and non-small cell lung carcinoma: The prolongation of progression-free survival (PFS) and improvement of symptoms and quality of life (QOL) in EGFR mutation-positive NSCLC treated with afatinib have been shown in several clinical trials [4,5,6,7,8,9,10,11,12,13,14,15].